Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanxining Tablets platelet target observational study
ChiCTR2300068637Phase 4Not yet recruiting
- Sponsor
- Xiyuan Hospital
- Start
- Feb 2023
- Countries
- 1
01
Overview
Phase 4, open-label trial of Guanxinning in coronary arteriosclerosis, angina pectoris and myocardial infarction (MI) (3 arms), sponsored by Xiyuan Hospital. Primary endpoint: Platelet proteomics. Planned start Feb 2023; status: not yet recruiting.
02
Drugs
Guanxinning
03
Conditions
coronary arteriosclerosisangina pectorismyocardial infarction (MI)
Beyond the preview
Go deeper on ChiCTR2300068637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300068637.